Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03636347 | A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. | PHASE2 | COMPLETED | 99 | — | — | Oct 1, 2018 | Mar 1, 2022 | Apr 13, 2022 | - | — |
| Name | Type | Description |
|---|---|---|
| Placebo Oral Tablet | DRUG | twice daily administration |
| Alvelestat oral tablet - dose 1 | DRUG | twice daily administration |
| Alvelestat oral tablet - dose 2 | DRUG | twice daily administration |